Unicentric Castleman’s disease. Symptoms, diagnostics and therapy
Authors:
Zdeněk Adam 1; Zdeněk Řehák 2; Zuzana Adamová 3; Renata Koukalová 2; Luděk Pour 1; Marta Krejčí 1; Ivanna Boichuk 1; Martin Krejčí 1; Martin Štork 1; Sabina Ševčíková 4; Zdeněk Král 1
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno
1; Oddělení nukleární medicíny, Masarykův onkologický ústav Brno
2; Chirurgické oddělení nemocnice Vsetín
3; Ústav patologické fyziologie LF MU Brno
4
Published in:
Vnitř Lék 2021; 67(8): 465-473
Category:
Review Articles
Overview
Castleman disease (CD) includes a group of rare and heterogeneous disorders with characteristic lymph node histopathological abnormalities. CD can occur in a single lymph node station, which is referred to as unicentric CD (UCD). CD can also involve multicentric lymphadenopathy and inflammatory symptoms – multicentric Castleman disease. The first-ever diagnostic and treatment guidelines were recently developed for UCD and published 2020. Complete surgical resection is often curative and is therefore the preferred first-line therapy, if possible. The management of unresectable UCD is more challenging. Existing evidence supports that asymptomatic unresectable UCD may be observed. The anti–interleukin-6 monoclonal antibody siltuximab should be considered for unresectable UCD patients with an inflammatory syndrome. Unresectable UCD that is symptomatic because of compression of vital neighbouring structures may be rendered amenable to resection by medical therapy (rituximab, steroids), radiotherapy, or embolization. In this article, we report about the symptoms of this disease and about the diagnostics recommendation published in the International, evidence-based consensus diagnostic criteria for HHV-8-negative/ idiopathic multicentric Castleman disease and about the therapeutic recommendation published in International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease published in the year 2020.
Keywords:
siltuximab – rituximab – Castleman’s disease
Sources
1. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence‑based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 2017; 129 (12): 1646–1657.
2. van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence‑based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20): 2115–2124.
3. van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence‑based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020;4(23): 6039–6050.
4. Castleman B, Towe VW. Case report of the Massachusetts General Hospital weekly clinicopathological exercises, fouded by Richard C Cabot. N Engl. J. Med 1954; 251 (10) 396-400.
5. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma.Cancer 1956; 9(4): 822–830.
6. Keller AR, Hochholzer L, Castleman B. Hyaline‑vascular and plasma‑cell types of giant lymph node hyperplasia of the mediastinum and other localisation. Cancer 1972; 29: 670–683.
7. Gaba AR Stein RS Sweet DJ et al. Multicentric giant node hyperplasia. Amer J Clin Pathol 1978; 69 (1): 86–90.
8. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma‑associated herpesvirus‑like DNA sequences in multicentric Castleman’s disease. Blood 1995; 86 (4): 1276–1280.
9. Chadbum A, Cesarman E, Nador RG, et al. Kaposi’s sarcoma – associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus. Cancer 1997; 80: 788–797.
10. Riu P, Noesl LH, Droz D, et al. Glomerular involvement in lymfoproliferative disorders with hyperproduction of cytokines (Castleman, POEMS) Adv Nephrol Necke Hosp 2000; 30: 305–331.
11. Masaki Y, Nakajima A, Iwao H, et al. Japanese variant of multicentric castleman’s disease associated with serositis and thrombocytopenia-- a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 2013; 53 (1): 79–85.
12. Kawabata H, Takai K, Kojima M, et al. Castleman‑Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : J Clin Exp Hematop 2013; 53 (1): 57–61.
13. Inoue M, Ankou M, Hua J, et al. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: A case report. J Clin Exp Hematop. 2013; 53 (1): 95–99.
14. Tedesco S, Postacchini L, Manfredi L, et al. Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with pathophysiology targeted therapy- case report. Exp Hematol Oncol 2015; 4 (1): 3–10.
15. Talat N, Schulte KM. Castleman’s disease: systematic analysis of 416 patients from the literature.Oncologist. 2011;16(9): 1316–1324.
16. Munshi N, Mehra M. van de Velde H, Desai A, et al. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 2015; 56(5): 1252–1260.
17. Caselli E, Padovani D, Di Carlo R et al. Parotid localized Castleman’s disease and HHV-8 infection: a case report. Head Neck Surg. 2008;265(3): 377–380.
18. Tóthová E, Fričová M, Sokol L. Castlemanova choroba Hematológia & Transfuziológia. 1993; 3 (1): 19–26.
19. Fichtle J, Treška V, Šulc R, et al. Castlemanova choroba – neobvyklý nález při operaci tumoru retroperitonea u mladého nemocného Rozhledy v chirurgii. 2016; 95 (2): 91-94.
20. Škach J, Vytiska J Gaalová R, et al. Castlemanova choroba imitující tumor perikardu. Kazuistiky v alergologii, pneumologii a ORL. 2014;11 (1): 3–7.
21. Zaválová Š, Jirák P, Syrůček M, et al. Castlemanova choroba – Mimicking a malignant lymphoma. Otorinolaryngologie a foniatrie. 2014; 63 (4): 246–250.
22. Szturz P, Plank L Křístek J, et al. Castlemanova choroba v obrazech. Postgraduální medicína. 2014; 16 (1): 81–88.
23. Rovenský J, Lee B, Kozák I. Castlemanova choroba – multicentrická angiofolikulární lymfoidní hyperplazie Oftalmorevmatologie. První vydání. Praha : Galén, 2017. 2017, s. 221–226.
24. Penka L., Kala Z, Zetelová A, et al. Castleman’s disease - surgical treatment, case reports Rozhledy v chirurgii. 2016; 95 (12): 457–461.
25. Jakubec P, Kolek V, Jakubcová T, et al.Castlemanova nemoc - asymptomatický tumor mediastina Studia pneumologica et phtiseologica. 2005; 65 (4):166–171.
26. Smolár M, Šutiak L, Mikolajčík A, et al. Lymfóm žalúdka ako príčina masívneho krvácania u pacienta s Castlemanovou chorobou. Rozhledy v chirurgii. 2010; 89 (5): 320–324.
27. Talat N, Belgaumkar AP Schulte KM. Surgery in Castleman’s disease: a systematic review of 404 published cases Ann Surg. 2012; 255(4):677–684).
28. FayandA, Boutboul D, Galicier L, et al. Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review. Amyloid.2019;26(4):197–202.
29. Raza HA, Nokes BT, Rosenthal AC, et al. Unicentric castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus.Respir Med Case Rep. 2018; 25:129–132.
30. Ohzono A,Sogame R, Li X, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173(6):1447–1452.
31. Gerald W, Kostianovsky M, Rosai J. Development of vascular neoplasia in Castleman’s disease. Report of seven cases. Am J Surg Pathol. 1990;14(7):603–614.
32. Chang KC, Wang YC, Hung LY, et al. Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease.Mod Pathol. 2014; 27(6):823–831.
33. Cokelaere K, Debiec‑Rychter M, De Wolf‑Peeters C, et al. Hyaline vascular Castleman’s disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis. Am J Surg Pathol.2002;26(5):662–669.
34. Pauwels P, Dal Cin P, Vlasveld LT, et al. A chromosomal abnormality in hyaline vascular Castleman’s disease: evidence for clonal proliferation of dysplastic stromal cells. Am J Surg Pathol. 2000;24(6):882–888.
35. Li Z, Lan X, Li C, et al. Recurrent PDGFRB mutations in unicentric Castleman disease. Leukemia. 2019; 33(4):1035–1038.
36. Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman’s disease. Am J Hematol. 2012; 87(11):997–1002.
37. Talat N; Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systematic review of 404 published cases.Ann Surg.2012; 255(4):677–684.
38. Boutboul D, Fadlallah J, Chawki S, et al. Treatment and outcome of unicentric Castleman disease: a retrospective analysis of 71 cases. Br J Haematol. 2019;186(2):269–273
39. Mohan M, Meek JC, Meek ME, et al. Combinatorial treatment for unresectable unicentric Castleman disease. Eur J Haematol. 2021 Jul 9. doi: 10.1111/ejh.13685.
40. Bandera B, Ainsworth C, Shikle J, et al. Treatment of unicentric Castleman disease with neoadjuvant rituximab. Chest. 2010;138(5):1239–1241.
41. Baek HJ, Kook H, Han DK, et al. Unicentric Castleman disease relapsed after rituximab‑CHOP chemotherapy or radiation therapy in an adolescent. J Pediatr Hematol Oncol. 2012; 34(5): e206–8.
42. Abid MB, Peck R, Abid MA, et al. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease? Hematol Oncol. 2018;36(1):320–323.
43. Fitzpatrick PJ, Brown TC. Angiofollicular lymph node hyperplasia. Can Med Assoc J. 1968;99(25):1259–1262. [PMC free article] [PubMed].
44. Nordstrom DG, Tewfik HH, Latourette HB. Plasma cell giant lymph node hyperplasia responding to radiation therapy. AJR Am J Roentgenol. 1978;130(1):169–171.
45. Stokes SH, Griffith RC, Thomas PR. Angiofollicular lymph node hyperplasia (Castleman’s disease) associated with vertebral destruction. Cancer. 1985;56(4):876–879.
46. Weisenburger DD, DeGowin RL, Gibson P, Armitage JO. Remission of giant lymph node hyperplasia with anemia after radiotherapy. Cancer. 1979;44(2):457–462.
47. Massey GV, Kornstein MJ, Wahl D, Huang XL, McCrady CW, Carchman RA. Angiofollicular lymph node hyperplasia (Castleman’s disease) in an adolescent female. Clinical and immunologic findings. Cancer. 1991;68(6):1365–1372.
48. Veldhuis GJ, van der Leest AH, de Wolf JT, de Vries EG, Vellenga E. A case of localized Castleman’s disease with systemic involvement: treatment and pathogenetic aspects. Ann Hematol. 1996;73(1):47–50. [PubMed]
49. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer. 1999;85(3):706–717.
50. Chronowski G M, Ha C S, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy Cancer 2001;92 (3): 670–676.
51. Neuhof D, Debus J. Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol. 2006;45(8):1126–1131.
52. Li YM, Liu PH, Zhang YH, et al. Radiotherapy of unicentric mediastinal Castleman’s disease. Chin J Cancer. 2011;30(5): 351–356.
53. Matthiesen C, Ramgopol R, Seavey J, et al. Intensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literature. Radiol Oncol 2012;46(3):265–270.
54. Miranda FA, Faria VH, Arruda GV, Silva LG. Radiation therapy in the treatment of unicentric Castleman’s disease. J Bras Pneumol. 2013;39(1):116–118.
55. Oksenhendler E, Boutboul D, Fajgenbaum D, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018;180(2):206–216.
56. Boutboul D, Fadlallah J, Chawki S, et al. Treatment and outcome of unicentric Castleman disease: a retrospective analysis of 71 cases. Br J Haematol. 2019;186(2):269–273
57. Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi‑organ syndrome. Respirology. 2009;14(1):129–133.
58. Dong Y, Wang M, Nong L, et al. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol. 2015;169(6):834–842.
59. Jain P, Milgrom SA, Patel KP, et al. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol. 2017;178(3):403–412.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2021 Issue 8
Most read in this issue
- SGLT2 inhibitors – a new pillar for the treatment of heart failure
- Renal parenchymal hypertension: relevant new aspects
- Optimal potassium levels in patients with heart failure
- Antibiotic treatment issues in patients with COVID-19